346 related articles for article (PubMed ID: 17725843)
1. Duloxetine in the treatment of major depressive disorder: an open-label study.
Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Bailey RK; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Natl Med Assoc; 2006 Mar; 98(3):437-47. PubMed ID: 16573311
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study.
Wohlreich MM; Mallinckrodt CH; Watkin JG; Hay DP
BMC Geriatr; 2004 Dec; 4():11. PubMed ID: 15585058
[TBL] [Abstract][Full Text] [Related]
14. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.
Wohlreich MM; Mallinckrodt CH; Watkin JG; Wilson MG; Greist JH; Delgado PL; Fava M
Ann Clin Psychiatry; 2005; 17(4):259-68. PubMed ID: 16402760
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
16. Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses.
Dunner DL; Wohlreich MM; Mallinckrodt CH; Watkin JG; Fava M
Curr Ther Res Clin Exp; 2005 Nov; 66(6):522-40. PubMed ID: 24678074
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
[TBL] [Abstract][Full Text] [Related]
18. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study.
Karp JF; Weiner DK; Dew MA; Begley A; Miller MD; Reynolds CF
Int J Geriatr Psychiatry; 2010 Jun; 25(6):633-42. PubMed ID: 19750557
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]